The small-molecule drugs known as senolytics selectively eliminate senescent cells. Senescent cells accumulate upon aging and are causative of multiple age-associated disorders. Thus, senescent cells are known to develop a senescence-associated secretory phenotype (SASP) to provoke immune clearance, which boosts chronic inflammation and plays a key role in aging and age-related diseases. It is believed that chronic inflammation activated by senescent cells is among the main grounds of aging-associated pathologies. Senolytic drugs are intended to delay, prevent, relieve, or treat such age-related diseases. As expected for therapeutics targeting one of the very fundamental aging mechanisms, the prospective uses of senolytics are variable, hopefully alleviating multiple conditions, opening a new route for curing age-related dysfunction and diseases.